On 17 October 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for Quizartinib for treating relapsed or refractory acute myeloid leukaemia. Therefore, this appraisal has been suspended. NICE will continue to monitor any developments and will update stakeholders if the situation changes.
Status
|
Suspended
|
Decision
|
Selected
|
Process |
STA 2018
|
ID number |
1325
|
Project Team
Project lead |
Louise Jafferally |
Email enquiries
Stakeholders
Companies sponsors |
Daiichi Sankyo (quizartinib) |
Others |
Department of Health |
|
NHS England |
|
Welsh Government |
Patient carer groups |
Bloodwise |
|
Leukaemia CARE |
Professional groups |
Association of Cancer Physicians |
|
British Society for Haematology |
|
Cancer Research UK |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
Comparator companies |
Pfizer (cytarabine, idarubicin) (confidentiality agreement signed) |
|
Accord Healthcare Ltd (cytarabine, etoposide, fludarabine, idarubicin, mitoxantrone) (confidentiality agreement not signed) |
|
Actavis (fludarabine) (confidentiality agreement not signed) |
|
Amgen (filgrastim) |
|
Hospira UK (cytarabine, fludarabine, filgrastim) (confidentiality agreement not signed) |
|
Napp Pharmaceuticals (cytarabine) (confidentiality agreement not signed) |
|
Sandoz (fludarabine, filgrastim) (confidentiality agreement not signed) |
|
Teva (fludarabine) (confidentiality agreement not signed) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
British National Formulary |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Scottish Medicines Consortium |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Institute of Cancer Research |
|
National Cancer Research Institute |
|
National Institute for Health Research |